Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

460 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes.
Visconte V, Rogers HJ, Singh J, Barnard J, Bupathi M, Traina F, McMahon J, Makishima H, Szpurka H, Jankowska A, Jerez A, Sekeres MA, Saunthararajah Y, Advani AS, Copelan E, Koseki H, Isono K, Padgett RA, Osman S, Koide K, O'Keefe C, Maciejewski JP, Tiu RV. Visconte V, et al. Among authors: rogers hj. Blood. 2012 Oct 18;120(16):3173-86. doi: 10.1182/blood-2012-05-430876. Epub 2012 Jul 23. Blood. 2012. PMID: 22826563 Free PMC article.
Clinical experiences with ruxolitinib in symptomatic patients with myeloproliferative neoplasm with chronic kidney disease.
Tabarroki A, Visconte V, Rogers HJ, Sekeres MA, Samaras C, Lichtin A, Duong HK, Englehaupt R, Cinalli T, Dodd K, Desamito J, Rouphail B, Altman JK, Stein BL, Tiu RV. Tabarroki A, et al. Among authors: rogers hj. Leuk Lymphoma. 2014 Jan;55(1):213-6. doi: 10.3109/10428194.2013.797086. Epub 2013 Jun 12. Leuk Lymphoma. 2014. PMID: 23607256 No abstract available.
Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with Sweet syndrome that was refractory to 5-azacitidine.
Liu Y, Tabarroki A, Billings S, Visconte V, Rogers HJ, Hasrouni E, Englehaupt R, Kalaycio M, Sekeres MA, Saunthararajah Y, Tiu RV. Liu Y, et al. Among authors: rogers hj. Leuk Lymphoma. 2014 Feb;55(2):447-9. doi: 10.3109/10428194.2013.802315. Epub 2013 Jun 24. Leuk Lymphoma. 2014. PMID: 23647061 No abstract available.
SF3B1 mutations are infrequently found in non-myelodysplastic bone marrow failure syndromes and mast cell diseases but, if present, are associated with the ring sideroblast phenotype.
Visconte V, Tabarroki A, Rogers HJ, Hasrouni E, Traina F, Makishima H, Hamilton BK, Liu Y, O'Keefe C, Lichtin A, Horwitz L, Sekeres MA, Hsieh FH, Tiu RV. Visconte V, et al. Among authors: rogers hj. Haematologica. 2013 Sep;98(9):e105-7. doi: 10.3324/haematol.2013.090506. Epub 2013 Jul 5. Haematologica. 2013. PMID: 23831919 Free PMC article. No abstract available.
Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.
Wang SA, Hasserjian RP, Fox PS, Rogers HJ, Geyer JT, Chabot-Richards D, Weinzierl E, Hatem J, Jaso J, Kanagal-Shamanna R, Stingo FC, Patel KP, Mehrotra M, Bueso-Ramos C, Young KH, Dinardo CD, Verstovsek S, Tiu RV, Bagg A, Hsi ED, Arber DA, Foucar K, Luthra R, Orazi A. Wang SA, et al. Among authors: rogers hj. Blood. 2014 Apr 24;123(17):2645-51. doi: 10.1182/blood-2014-02-553800. Epub 2014 Mar 13. Blood. 2014. PMID: 24627528 Free PMC article.
Ruxolitinib in combination with DNA methyltransferase inhibitors: clinical responses in patients with symptomatic myelofibrosis with cytopenias and elevated blast(s) counts.
Tabarroki A, Saunthararajah Y, Visconte V, Cinalli T, Colaluca K, Rogers HJ, Sekeres MA, Duong HK, Stein BL, Tiu RV. Tabarroki A, et al. Among authors: rogers hj. Leuk Lymphoma. 2015 Feb;56(2):497-9. doi: 10.3109/10428194.2014.916805. Epub 2014 May 27. Leuk Lymphoma. 2015. PMID: 24766471 No abstract available.
460 results